Open AccessBiopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics
Author(s) -
Kumar Sandeep,
Plotnikov Nikolay V.,
Rouse Jason C.,
Singh Satish K.
Publication year - 2018
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1111/jphp.12700
Subject(s) - biopharmaceutical , informatics , drug development , translational research informatics , drug discovery , computer science , new product development , data science , product (mathematics) , health informatics , drug , biochemical engineering , engineering , pharmacology , medicine , health administration informatics , bioinformatics , microbiology and biotechnology , business , biology , geometry , electrical engineering , nursing , mathematics , marketing , public health
Abstract Objectives The purpose of this article is to introduce an emerging field called ‘Biopharmaceutical Informatics’. It describes how tools from Information technology and Molecular Biophysics can be adapted, developed and gainfully employed in discovery and development of biologic drugs. Key Findings The findings described here are based on literature surveys and the authors’ collective experiences in the field of biologic drug product development. A strategic framework to forecast early the hurdles faced during drug product development is weaved together and elucidated using chemical degradation as an example. Efficiency of translating biologic drug discoveries into drug products can be significantly improved by combining learnings from experimental biophysical and analytical data on the drug candidates with molecular properties computed from their sequences and structures via molecular modeling and simulations. Summary Biopharmaceutical Informatics seeks to promote applications of computational tools towards discovery and development of biologic drugs. When fully implemented, industry‐wide, it will enable rapid materials‐free developability assessments of biologic drug candidates at early stages as well as streamline drug product development activities such as commercial scale production, purification, formulation, analytical characterization, safety and in vivo performance.